FDA Could Act to Pull More Opioid Pain Pills From the U.S. Market
- On Thursday, agency said Endo should stop sale of pill Opana
- Drug agency’s action comes amid epidemic of addiction, deaths
FDA Makes Opioid Abuse a Top Priority
This article is for subscribers only.
The Food and Drug Administration is examining the abuse potential of several more opioid pain pills amid an ongoing review of health risks from the drugs, which have been tied to thousands of overdose deaths a year.
On Thursday, the FDA asked Endo International Plc to stop sales of its powerful opioid painkiller Opana ER, the first time the agency has taken such a step. The request was made after the drug was tied to outbreaks of viral infections including HIV, as addicts would inject the drug and spread disease by sharing needles.